Use of cardiac biomarkers in neonatology

Pediatric Research

Volumn 72, Issue 4, 2012, Pages 337-343

  Vijlbrief, Daniel C ^a   Benders, Manon J N L ^a   Kemperman, Hans ^b   Van Bel, Frank ^a   De Vries, Willem B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; CREATINE KINASE MB; TROPONIN I; TROPONIN T;

HEART FUNCTION; HUMAN; INTRAUTERINE GROWTH RETARDATION; LUNG DYSPLASIA; NEWBORN DISEASE; NORMAL VALUE; PATENT DUCTUS ARTERIOSUS; PERINATAL ASPHYXIA; PERSISTENT PULMONARY HYPERTENSION; PRIORITY JOURNAL; REVIEW; SEPSIS;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; HEART DISEASES; HUMANS; INFANT, NEWBORN; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NEONATOLOGY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TROPONIN;

EID: 84867044698     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2012.88     Document Type: Review

References (79)

1. Trevisanuto D, Picco G, Golin R, et al. Cardiac troponin I in asphyxiated neonates. Biol Neonate 2006;89:190-3.
2. El-Khuffash A, Davis PG, Walsh K, Molloy EJ. Cardiac troponin T and N-terminal-pro-B type natriuretic peptide reflect myocardial function in preterm infants. J Perinatol 2008;28:482-6.
3. Attridge JT, Kaufman DA, Lim DS. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2009;94:F178-82.
4. El-Khuffash AF, Slevin M, McNamara PJ, Molloy EJ. Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants. Arch Dis Child Fetal Neonatal Ed 2011;96:F133-7.
5. Czernik C, Lemmer J, Metze B, Koehne PS, Mueller C, Obladen M. B-type natriuretic peptide to predict ductus intervention in infants 28 weeks. Pediatr Res 2008;64:286-90
6. El-Khuffash A, Molloy EJ. Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates? Arch Dis Child Fetal Neonatal Ed 2007;92:F320-4.
7. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.
8. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 1992;267:13928-32.
9. Woodard GE, Rosado JA, Brown J. Expression and control of C-type natriuretic peptide in rat vascular smooth muscle cells. Am J Physiol Regul Integr Comp Physiol 2002;282:R156-65.
10. Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care 2004;10:336-41.
11. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-84.
12. Mir TS, Laux R, Hellwege HH, et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003;112:896-9.
13. Holmstr H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001;90:184-91.
14. Breuer T, Si E, Skoumal R, et al. N-terminal probrain natriuretic peptide level inversely correlates with cardiac index after arterial switch operation in neonates. Paediatr Anaesth 2007;17:782-8.
15. Nir A, Lindinger A, Rauh M, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3-8.
16. Mannarino S, Garofoli F, Mongini E, et al. BNP concentrations and cardiovascular adaptation in preterm and fullterm newborn infants. Early Hum Dev 2010;86:295-8.
17. Gemelli M, Mam C, Manganaro R, Stelitano L, Bonaccorsi P, Martino F. Effects of the mode of delivery on ANP and renin-aldosterone system in the fetus and the neonate. Eur J Obstet Gynecol Reprod Biol 1992;43:181-4.
18. Seong WJ, Yoon DH, Chong GO, et al. Umbilical cord blood amino-terminal pro-brain natriuretic peptide levels according to the mode of delivery. Arch Gynecol Obstet 2010;281:907-12.
19. Fortunato G, Carandente Giarrusso P, Martinelli P, et al. Cardiac troponin T and amino-terminal pro-natriuretic peptide concentrations in fetuses in the second trimester and in healthy neonates. Clin Chem Lab Med 2006;44:834-6.
20. Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinman CS. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005;147:38-42.
21. Omokhodion SI, Losekoot TG, Jaiyesimi F. Serum creatine kinase and creatine kinase-MB isoenzyme activities in perinatally asphyxiated newborns. Eur Heart J 1991;12:980-4.
22. Tker G, Babaoglu K, Galp AS, Sarper N, Zengin E, Arisoy AE. Cord blood cardiac troponin I as an early predictor of short-term outcome in perinatal hypoxia. Biol Neonate 2004;86:131-7.
23. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999;45:1104-21.
24. Anderson PA, Malouf NN, Oakeley AE, Pagani ED, Allen PD. Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res 1991;69:1226-33.
25. Gaze DC, Collinson PO. Cardiac troponin I should be interpreted with caution in paediatric neonatal patients. Concerning Turker et al.: 'Cord blood cardiac troponin I as an early predictor of short-term outcome in perinatal hypoxia'. Biol Neonate 2005;87:19.
26. Iacovidou N, Boutsikou M, Gourgiotis D, et al. Perinatal changes of cardiac troponin-I in normal and intrauterine growth-restricted pregnancies. Mediators Inflamm 2007;2007:53921.
27. Trevisanuto D, Doglioni N, Altinier S, Zaninotto M, Plebani M, Zanardo V. Cardiac troponin I at birth is of fetal-neonatal origin. Arch Dis Child Fetal Neonatal Ed 2009;94:F464-6.
28. Shelton SD, Fouse BL, Holleman CM, Sedor FA, Herbert WN. Cardiac troponin T levels in umbilical cord blood. Am J Obstet Gynecol 1999;181(5 Pt 1):1259-62.
29. Bodor GS, Porterfield D, Voss EM, Smith S, Apple FS. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995;41(12 Pt 1):1710-5.
30. Sasse S, Brand NJ, Kyprianou P, et al. Troponin I gene expression during human cardiac development and in end-stage heart failure. Circ Res 1993;72:932-8.
31. El-Khuffash AF, Molloy EJ. Serum troponin in neonatal intensive care. Neonatology 2008;94:1-7.
32. Trevisanuto D, Zaninotto M, Altinier S, Plebani M, Zanardo V. High serum cardiac troponin T concentrations in preterm infants with respiratory distress syndrome. Acta Paediatr 2000;89:1134-6.
33. Clark SJ, Newland P, Yoxall CW, Subhedar NV. Cardiac troponin T in cord blood. Arch Dis Child Fetal Neonatal Ed 2001;84:F34-7.
34. McAuliffe F, Mears K, Fleming S, Grimes H, Morrison JJ. Fetal cardiac troponin I in relation to intrapartum events and umbilical artery pH. Am J Perinatol 2004;21:147-52.
35. Crispi F, Hernandez-Andrade E, Pelsers MM, et al. Cardiac dysfunction and cell damage across clinical stages of severity in growth-restricted fetuses. Am J Obstet Gynecol 2008;199:254.e1-8.
36. Girsen A, Ala-Kopsala M, Mikallio K, Vuolteenaho O, Ren J. Cardiovascular hemodynamics and umbilical artery N-terminal peptide of proB-type natriuretic peptide in human fetuses with growth restriction. Ultrasound Obstet Gynecol 2007;29:296-303.
37. Crispi F, Comas M, Herndez-Andrade E, et al. Does pre-eclampsia influence fetal cardiovascular function in early-onset intrauterine growth restriction? Ultrasound Obstet Gynecol 2009;34:660-5.
38. Mikallio K, Vuolteenaho O, Jouppila P, Ren J. Ultrasonographic and biochemical markers of human fetal cardiac dysfunction in placental insufficiency. Circulation 2002;105:2058-63.
39. Adamcov M, Kokstein Z, Palicka V, VrovJ, Podholov M, Kost' M. Cardiac troponin T in neonates after acute and long-term tocolysis. Biol Neonate 2000;78:288-92.
40. Karadeniz L, Coban A, Ince Z, Turkoglu U, Can G. Cord blood cardiac troponin T and nonprotein-bound iron levels in newborns of mild preeclamptic mothers. Neonatology 2010;97:305-10.
41. Mikallio K, Vuolteenaho O, Jouppila P, Ren J. Association of severe placental insufficiency and systemic venous pressure rise in the fetus with increased neonatal cardiac troponin T levels. Am J Obstet Gynecol 2000;183:726-31.
42. Zhang ZL, Lin LX, An CX, Tao ZB, Yang M. [Changes of N-terminal probrain natriuretic peptide in neonates with myocardial ischemic injury]. Zhongguo Dang Dai Er Ke Za Zhi 2009;11:973-5.
43. Vijlbrief DC, Benders MJNL, Kemperman H, et al. Cardiac biomarkers as indicators of hemodynamic adaptation during postasphyxial hypothermia treatment. Neonatology 2012;102:243-8 (doi: 10.1159/000339117).
44. Bertinchant JP, Larue C, Pernel I, et al. Release kinetics of serum cardiac troponin I in ischemic myocardial injury. Clin Biochem 1996;29:587-94.
45. Mler JC, Thielsen B, Schaible TF, et al. Value of myocardial hypoxia markers (creatine kinase and its MB-fraction, troponin-T, QT-intervals) and serum creatinine for the retrospective diagnosis of perinatal asphyxia. Biol Neonate 1998;73:367-74.
46. Szymankiewicz M, Matuszczak-Wleklak M, Hodgman JE, Gadzinowski J. Usefulness of cardiac troponin T and echocardiography in the diagnosis of hypoxic myocardial injury of full-term neonates. Biol Neonate 2005;88:19-23.
47. Costa S, Zecca E, De Rosa G, et al. Is serum troponin T a useful marker of myocardial damage in newborn infants with perinatal asphyxia? Acta Paediatr 2007;96:181-4.
48. Liu X, Tooley J, Lerg EM, Suleiman MS, Thoresen M. Immediate hypothermia reduces cardiac troponin I after hypoxic-ischemic encephalopathy in newborn pigs. Pediatr Res 2011;70:352-6.
49. Shastri AT, Samarasekara S, Muniraman H, Clarke P. Cardiac troponin I concentrations in neonates with hypoxic-ischaemic encephalopathy. Acta Paediatr 2012;101:26-9.
50. Ges T, Oztk MA, Narin N, KlE. Troponin-T levels in perinatally asphyxiated infants during the first 15 days of life. Acta Paediatr 2005;94:1638-43.
51. King DA, Codish S, Novack V, Barski L, Almog Y. The role of cardiac troponin I as a prognosticator in critically ill medical patients: a prospective observational cohort study. Crit Care 2005;9:R390-5.
52. Evers AC, van Leeuwen J, Kwee A, et al. [Mortality and morbidity among full-term neonates in a neonatal intensive care unit in the Utrecht region, the Netherlands]. Ned Tijdschr Geneeskd 2010;154:A118.
53. Boo NY, Hafidz H, Nawawi HM, et al. Comparison of serum cardiac troponin T and creatine kinase MB isoenzyme mass concentrations in asphyxiated term infants during the first 48 h of life. J Paediatr Child Health 2005;41:331-7.
54. Kanik E, Ozer EA, Bakiler AR, et al. Assessment of myocardial dysfunction in neonates with hypoxic-ischemic encephalopathy: is it a significant predictor of mortality? J Matern Fetal Neonatal Med 2009;22:239-42.
55. Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008;93:F257-60.
56. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L'Ecuyer T. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005;25:709-13.
57. Nuntnarumit P, Khositseth A, Thanomsingh P. N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants. J Perinatol 2009;29:137-42.
58. Ramakrishnan S, Heung YM, Round J, Morris TP, Collinson P, Williams AF. Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants. Acta Paediatr 2009;98:1254-9.
59. El-Khuffash AF, Amoruso M, Culliton M, Molloy EJ. N-terminal pro-Btype natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: a prospective observational study. Arch Dis Child Fetal Neonatal Ed 2007;92:F421-2.
60. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005;115:e255-61.
61. Chen S, Tacy T, Clyman R. How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude? J Perinatol 2010;30:780-5.
62. Hammerman C, Shchors I, Schimmel MS, Bromiker R, Kaplan M, Nir A. N-terminal-pro-B-type natriuretic peptide in premature patent ductus arteriosus: a physiologic biomarker, but is it a clinical tool? Pediatr Cardiol 2010;31:62-5.
63. Hsu JH, Yang SN, Chen HL, Tseng HI, Dai ZK, Wu JR. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. J Pediatr 2010;157:79-84.
64. El-Khuffash A, Barry D, Walsh K, Davis PG, Molloy EJ. Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage. Arch Dis Child Fetal Neonatal Ed 2008;93:F407-12.
65. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007;92:F424-7.
66. El-Khuffash AF, Molloy EJ. Influence of a patent ductus arteriosus on cardiac troponin T levels in preterm infants. J Pediatr 2008;153:350-3.
67. Trevisanuto D, Zaninotto M, Lachin M, et al. Effect of patent ductus arteriosus and indomethacin treatment on serum cardiac troponin T levels in preterm infants with respiratory distress syndrome. Eur J Pediatr 2000;159:273-6.
68. Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2009;135:745-51.
69. Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114:1297-304.
70. Vijlbrief DC, Benders MJ, Kemperman H, van Bel F, de Vries WB. B-type natriuretic peptide and rebound during treatment for persistent pulmonary hypertension. J Pediatr 2012;160:111-5.e1.
71. Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ. N-terminal pro-Btype natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004;93:603-7.
72. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003;108:844-8.
73. Kim GB. Pulmonary hypertension in infants with bronchopulmonary dysplasia. Korean J Pediatr 2010;53:688-93.
74. Farquhar M, Fitzgerald DA. Pulmonary hypertension in chronic neonatal lung disease. Paediatr Respir Rev 2010;11:149-53.
75. Mourani PM, Ivy DD, Rosenberg AA, Fagan TE, Abman SH. Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatr 2008;152:291-3.
76. Joseph L, Nir A, Hammerman C, Goldberg S, Ben Shalom E, Picard E. N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. Am J Perinatol 2010;27:381-6.
77. Rudiger A, Gasser S, Fischler M, Hornemann T, von Eckardstein A, Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006;34:2140-4.
78. Domico M, Liao P, Anas N, Mink RB. Elevation of brain natriuretic peptide levels in children with septic shock. Pediatr Crit Care Med 2008;9:478-83.
79. Clark SJ, Newland P, Yoxall CW, Subhedar NV. Concentrations of cardiac troponin T in neonates with and without respiratory distress. Arch Dis Child Fetal Neonatal Ed 2004;89:F348-52.